Biomarkers /
BCL6
Overview
B-cell CLL/lymphoma 6 (BCL6) is a gene that encodes a protein that is a zinc finger transcription factor. The protein functions in transcriptional repression and the regulation of interleukin dependent responses in B-cells. Missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame deletions are observed in cancers such as esophageal cancer, intestinal cancer, and stomach cancer.
BCL6 is altered in 1.64% of all cancers with lung adenocarcinoma, colon adenocarcinoma, squamous cell lung carcinoma, endometrial endometrioid adenocarcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in BCL6 are BCL6 Amplification (0.40%), BCL6 Fusion (0.13%), BCL6 Loss (0.06%), BCL6-EIF4A2 Fusion (0.10%), and BCL6 R618C (0.03%) [3].
Clinical Trials
Significance of BCL6 in Diseases
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma +
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.